Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. launched Regulus Therapeutics LLC, a joint venture focused on the discovery, development, and commercialization of microRNA (miRNA) therapeutics. These therapeutics represent a new approach to target the pathways of human disease. Regulus will combine Isis’ and Alnylam’s technologies and intellectual property with leadership from a management team and Scientific Advisory Board to be chaired by Nobel laureate David Baltimore...